Filiuk I. O., Kalbus O. I.

DEPRESSION AND ANXIETY IN PATIENTS WHO HAVE HAD COVID-19

---

Show/Download

About the author:

Filiuk I. O., Kalbus O. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

This article presents an analysis of studies on neurological complications in patients with coronavirus disease. COVID-19 affects various systems of the body, and the article is primarily aimed at identifying complications from both the central and peripheral nervous systems, the development of further mental disorders, such as depression and anxiety, which can occur at different stages of the disease. The study was aimed at establishing the relationship between the severity of the disease and the course of neurological complications after COVID-19. According to the literature, the definition of post-COVID syndrome is a syndrome that lasts more than 12 weeks from the onset of the disease and can manifest itself in mental disorders, depression, anxiety, dyssomnia, cognitive impairment, and, most importantly, impaired quality of life in these patients. This study, 100 patients were examined, 69 in the main group and 31 in the control group. All patients were assessed for cognitive changes using the MoCA scale, depression was assessed using the Beck Depression Inventory, and indicators of situational and personal anxiety were interpreted using the Spielberger State-Trait Anxiety Inventory (STAI). The study also established the relationship between the development of depression and anxiety in patients with COVID-19, both at the onset of the disease and after 6 months of examination, and the concentration of neurofilament chains, which can be characterized by axonal damage. The development of anxiety and depression from the onset of the disease and its persistence after 6 months allows us to track the dynamics of the progression of the neurodegenerative process. Timely and early diagnosis of neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease and many others, and above all, a detailed study of neurofilament biomarkers as a prognostic marker requires the attention of doctors of all specialities.

Tags:

Bibliography:

1. Bourgonje AR, Abdulle AE, Timens W, Hillebrands J-L, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARSCoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228-48. DOI: https://doi.org/10.1002/path.5471.
2. Bao Y, Sun Y, Meng S, Shi J, Lu L. 2019-nCoV epidemic: address mental health care to empower society. Lancet. 2020;395(10224):e37-e38. DOI: https://doi.org/10/1016/S0140-6736(20)30.
3. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Network Open. 2020;3(9):e2019686-e2019686. DOI: https://doi.org/10.1001/jamanetworkopen.2020.19686.
4. Taylor S, Asmundson GJG. Life in a post-pandemic world: What to expect of anxiety-related conditions and their treatment. J Anxiety Disord. 2020;72:102231. DOI: 10.1016/j.janxdis.2020.102231.
5. Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: Epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. 2022;36(7):681-702. DOI: https://doi.org/10.1007/s40263-022-00931-3.
6.  Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. DOI: https://doi.org/10.1136/bmj.n136.
7. Nettis MA, Pariante CM, Mondelli V. Early-life adversity, systemic inflammation and comorbid physical and psychiatric illnesses of adult life. Curr Top Behav Neurosci. 2020;44:207-25. DOI: https://doi.org/10.1007/7854_2019_89.
8. Verkhratsky A, Rodríguez JJ, Steardo L. Astrogliopathology: a central element of neuropsychiatric diseases?: A central element of neuropsychiatric diseases? Neuroscientist. 2014;20(6):576-88. DOI: https://doi.org/10.1177/1073858413510208.
9. Artal C. Complicaciones neurológicas por coronavirus y COVID-19. Revista de Neurología. 2020;70(9):311-322.
10. Berlit P, Bösel J, Gahn G, Isenmann S, Meuth SG, Nolte CH, et al. Neurological manifestations of COVID-19 – guideline of the German society of neurology. Neurol Res Pract. 2020;2(1):51. DOI: https://doi.org/10.1186/s42466-020-00097-7.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 1, 176, 314-322 pages, index UDC 616.98:578.834COVID-19]-06:[616.89-008.454:616.891.6]-07

DOI:

10.29254/2077-4214-2025-1-176-314-322